FDA and the R&D Crisis: Time to Stop the Blame Game
This article was originally published in RPM Report
Executive Summary
Everyone knows R&D productivity has dipped to levels that threaten the private drug development model, and almost everyone says regulatory hurdles are part of the problem. That isn’t how FDA sees it. One thing is clear: blaming FDA won’t help anyone, so it may be time to pay more attention to FDA’s ideas for solutions rather than continue to point fingers.
You may also be interested in...
COPD Patient-Reported Outcome Questionnaire Is Early Example of FDA Drug Development Tool “Approval” Process
FDA finalizes the "qualification process for drug development tools." The topic won't get as much attention as Breakthrough Therapy or Accelerated Approval, but the head of the drug center thinks this is a very big deal. A COPD outcomes assessment is an early example of the process in action.
Cruel Summer: High-Profile Trial Failures Dominate R&D News Flow
As the summer of 2012 wears on, an outpouring of negative clinical trial news for high-profile new drug candidates has made the season more a time of doldrums than of fun in the sun for big pharma.
Cruel Summer: High-Profile Trial Failures Dominate R&D News Flow
As the summer of 2012 wears on, an outpouring of negative clinical trial news for high-profile new drug candidates has made the season more a time of doldrums than of fun in the sun for big pharma.